Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.

Journal of cardiovascular pharmacology and therapeutics - 1 Jan 2000

Azzahhafi Jaouad, Broek Wout W A van den, Chan Pin Yin Dean R P P, Harmsze Ankie M, van Schaik Ron H N, Ten Berg Jurriën M

Abstract excerpt

BACKGROUND: Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome (ACS) patients. However, these P2Y12 inhibitors increase bleeding risk compared to clopidogrel. Although genotype-guided P2Y12-inhibitor selection has been shown to reduce bleeding risk, data on its clinical implementation is lacking. METHODS: The study included ACS patients receiving genotype-guided antiplatelet therapy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Percutaneous Coronary Intervention

Share to Platelet Aggregation Inhibitors

Share to Prasugrel Hydrochloride

Share to Ticagrelor

Share to Treatment Outcome

Source

Identifiers

PMID: 37899583
DOI: 10.1177/10742484231210704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.PMID 37899583Read ↗

A Genotype-Guided P2Y12-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence from the POPULAR-GUIDE PCISemantic proximity Read ↗

2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping.Semantic proximity Read ↗

Genotype-Guided P2Y12-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI.Semantic proximity Read ↗

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.Semantic proximity Read ↗

Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.Semantic proximity Read ↗

Development and Validation of a Rapid Point-of-Care CYP2C19 Genotyping PlatformSemantic proximity Read ↗

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary InterventionSemantic proximity Read ↗

Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors.Semantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial.Semantic proximity Read ↗

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Semantic proximity Read ↗

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.